BCRX - BioCryst Pharmaceuticals Inc Stock Price, Fair Value and News

5.10USD-0.16 (-3.04%)Market Closed

Market Summary

USD5.10-0.16

Market Closed

-3.04%

BCRX Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)
Losses in recent quarter

BCRX Stock Price

View Fullscreen

BCRX RSI Chart

BCRX Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-5.05

Price/Sales (Trailing)

2.96

EV/EBITDA

-12.56

Price/Free Cashflow

-10.39

BCRX Price/Sales (Trailing)

BCRX Profitability

EBT Margin

-58.69%

Return on Equity

43.81%

Return on Assets

-44.58%

Free Cashflow Yield

-9.63%

BCRX Fundamentals

BCRX Revenue

Revenue (TTM)

355.4M

Rev. Growth (Yr)

34.87%

Rev. Growth (Qtr)

-0.69%

BCRX Earnings

Earnings (TTM)

-208.6M

Earnings Growth (Yr)

33.66%

Earnings Growth (Qtr)

42.69%

Breaking Down BCRX Revenue

Last 7 days

11.6%

Last 30 days

10.6%

Last 90 days

-4.1%

Trailing 12 Months

-40.6%

How does BCRX drawdown profile look like?

BCRX Financial Health

Current Ratio

3.73

Debt/Equity

-0.65

Debt/Cashflow

-0.33

BCRX Investor Care

Shares Dilution (1Y)

9.23%

Diluted EPS (TTM)

-1.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	355.4M	0	0	0
2023	289.7M	306.6M	317.6M	331.4M
2022	188.0M	203.6M	238.4M	270.8M
2021	32.0M	79.1M	114.0M	157.2M
2020	47.8M	49.2M	53.5M	17.8M
2019	22.6M	11.5M	11.8M	48.8M
2018	19.7M	29.1M	21.8M	20.7M
2017	31.0M	29.3M	30.3M	25.2M
2016	46.3M	25.2M	22.0M	26.4M
2015	17.0M	41.4M	49.1M	48.3M
2014	17.2M	17.9M	18.7M	13.6M
2013	16.2M	12.8M	12.3M	17.3M
2012	26.4M	26.9M	24.5M	24.8M
2011	41.7M	37.9M	31.1M	19.6M
2010	0	70.5M	66.5M	62.4M
2009	0	0	0	74.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of BioCryst Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	thackray helen m.	sold (taxes)	-38,227	5.08	-7,525	chief r&d officer
Feb 29, 2024	milano vincent	acquired	5,624	5.63	999	-
Feb 29, 2024	heggie theresa	acquired	5,624	5.63	999	-
Jan 03, 2024	stonehouse jon p	gifted	-	-	-20,000	president & ceo
Jan 03, 2024	stonehouse jon p	gifted	-	-	10,000	president & ceo
Dec 19, 2023	barnes alane p	sold (taxes)	-15,016	6.05	-2,482	chief legal officer
Dec 19, 2023	stonehouse jon p	sold (taxes)	-85,238	6.05	-14,089	president & ceo
Dec 19, 2023	gayer charles k	sold (taxes)	-15,016	6.05	-2,482	chief commercial officer
Dec 19, 2023	thackray helen m.	sold (taxes)	-33,759	6.05	-5,580	chief r&d officer

Which funds bought or sold BCRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	added	7.45	-32,000	322,000	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	233	3,668,290	5,674,140	-%
May 07, 2024	SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC	new	-	326,974	326,974	0.01%
May 07, 2024	PANAGORA ASSET MANAGEMENT INC	reduced	-5.46	-794,311	3,213,400	0.02%
May 07, 2024	Swiss National Bank	reduced	-2.54	-388,116	1,848,960	-%
May 07, 2024	Inspire Investing, LLC	added	9.7	-26,430	352,887	0.04%
May 07, 2024	CarsonAllaria Wealth Management, Ltd.	unchanged	-	-210	1,168	-%
May 07, 2024	SEI INVESTMENTS CO	added	7.84	-20,055	214,546	-%
May 07, 2024	ASSETMARK, INC	added	76.67	5,820	17,501	-%
May 07, 2024	Arizona State Retirement System	reduced	-4.37	-59,959	257,343	-%

Are Funds Buying or Selling BCRX?

Are funds buying BCRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BCRX

No. of Funds

Unveiling BioCryst Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	avoro capital advisors llc	6.4%	13,050,000	SC 13G
Feb 14, 2024	baker bros. advisors lp	4.94%	10,126,176	SC 13G/A
Feb 13, 2024	vanguard group inc	8.67%	17,763,720	SC 13G/A
Jan 24, 2024	state street corp	6.24%	12,777,003	SC 13G/A
Jan 24, 2024	blackrock inc.	9.1%	18,681,370	SC 13G/A
Feb 14, 2023	baker bros. advisors lp	9.91%	19,106,881	SC 13G/A
Feb 09, 2023	vanguard group inc	7.62%	14,204,395	SC 13G/A
Feb 06, 2023	state street corp	5.97%	11,126,861	SC 13G/A
Feb 03, 2023	blackrock inc.	8.0%	14,918,955	SC 13G/A
Feb 14, 2022	baker bros. advisors lp	9.91%	18,386,831	SC 13G/A

Recent SEC filings of BioCryst Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Apr 02, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Feb 27, 2024	S-3ASR	S-3ASR
Feb 27, 2024	10-K	Annual Report

Peers (Alternatives to BioCryst Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.8	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.13	14.32	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-46.06	3.89	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

BioCryst Pharmaceuticals Inc News

Latest updates

BioCryst Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-0.7%	92,761,000	93,401,000	86,742,000	82,491,000	68,778,000	79,545,000	75,827,000	65,532,000	49,923,000	47,158,000	40,994,000	49,959,000	19,059,000	4,016,000	6,102,000	2,871,000	4,823,000	39,725,000	1,775,000	1,448,000	5,887,000
Costs and Expenses	-21.2%	107,249,000	136,071,000	98,663,000	103,194,000	97,193,000	125,856,000	93,272,000	100,254,000	99,880,000	99,335,000	85,578,000	79,541,000	70,436,000	56,421,000	48,966,000	41,381,000	45,801,000	39,834,000	36,873,000	36,366,000	35,217,000
S&GA Expenses	-7.8%	59,364,000	64,382,000	50,648,000	50,997,000	47,867,000	50,153,000	36,919,000	38,017,000	34,282,000	35,387,000	34,992,000	26,325,000	22,114,000	20,986,000	17,195,000	13,883,000	15,865,000	10,489,000	11,735,000	8,659,000	6,238,000
R&D Expenses	-33.6%	46,493,000	70,052,000	46,879,000	51,247,000	48,388,000	73,207,000	52,740,000	61,990,000	65,360,000	63,529,000	49,971,000	52,873,000	42,435,000	35,354,000	30,245,000	27,498,000	29,867,000	26,774,000	25,120,000	27,681,000	27,493,000
EBITDA Margin	18.5%	-0.29	-0.35	-0.39	-0.43	-0.41	-0.53	-0.40	-0.61	-0.64	-0.77	-1.19	-1.86	-	-	-	-	-	-	-	-	-
Interest Expenses	-0.3%	24,506,000	24,583,000	27,345,000	28,915,000	27,396,000	26,458,000	24,775,000	24,022,000	23,837,000	18,780,000	14,115,000	13,495,000	12,904,000	5,609,000	2,927,000	2,918,000	3,047,000	3,087,000	3,044,000	3,035,000	2,726,000
Income Taxes	125.5%	365,000	-1,431,000	330,000	740,000	671,000	76,000	1,522,000	856,000	279,000	2,253,000	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	44.6%	-35,014,000	-63,162,000	-35,819,000	-74,586,000	-52,662,000	-71,465,000	-40,998,000	-58,003,000	-73,917,000	-15,526,000	-58,801,000	-43,198,000	-64,284,000	-	-	-	-	-	-	-	-
EBT Margin	14.0%	-0.59	-0.68	-0.74	-0.78	-0.77	-0.90	-0.79	-1.01	-1.02	-1.16	-1.60	-2.31	-	-	-	-	-	-	-	-	-
Net Income	42.7%	-35,379,000	-61,731,000	-36,149,000	-75,326,000	-53,333,000	-71,541,000	-42,520,000	-58,859,000	-74,196,000	-17,779,000	-58,801,000	-43,198,000	-64,284,000	-60,493,000	-46,115,000	-38,607,000	-37,599,000	-2,622,000	-37,592,000	-37,629,000	-31,054,000
Net Income Margin	14.1%	-0.59	-0.68	-0.74	-0.79	-0.78	-0.91	-0.81	-1.03	-1.03	-1.17	-1.99	-2.71	-	-	-	-	-	-	-	-	-
Free Cashflow	-502.0%	-53,684,000	-8,918,000	-19,897,000	-18,814,000	-47,512,000	-23,849,000	-32,444,000	-27,757,000	-77,800,000	-32,459,000	-23,276,000	-25,411,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.5%	468	517	523	530	510	550	559	511	528	588	266	277	284	335	176	215	137	175	91.00	116	142
Current Assets	-9.9%	447	496	502	511	491	517	509	495	512	566	253	266	274	324	162	204	126	164	79.00	104	118
Cash Equivalents	-23.8%	84.00	111	151	146	155	305	247	273	396	504	200	210	227	272	96.00	173	102	114	30.00	31.00	35.00
Inventory	3.8%	30.00	29.00	30.00	27.00	27.00	28.00	27.00	23.00	16.00	16.00	14.00	10.00	5.00	7.00	6.00	5.00	-	-	2.00	1.00	1.00
Net PPE	-1.0%	8.00	8.00	9.00	8.00	8.00	9.00	8.00	9.00	9.00	9.00	8.00	8.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	8.00	8.00
Current Liabilities	-20.0%	120	150	91.00	93.00	85.00	106	82.00	95.00	81.00	104	134	116	101	106	112	103	93.00	92.00	82.00	72.00	66.00
Long Term Debt	1.7%	308	303	298	293	233	232	224	145	140	136	132	127	123	120	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	303	298	293	233	232	224	145	140	136	132	127	123	120	-	-	-	-	-	-	-
Shareholder's Equity	-4.5%	-476	-455	-	-	-328	-294	-	-	-	-	-	-	-	-	34.00	77.00	4.00	38.00	-	-	23.00
Retained Earnings	-2.1%	-1,716	-1,681	-1,619	-1,583	-1,507	-1,454	-1,383	-1,340	-1,281	-1,207	-1,189	-1,130	-1,087	-1,023	-962	-916	-878	-840	-838	-800	-762
Additional Paid-In Capital	1.3%	1,238	1,222	1,206	1,192	1,177	1,158	1,139	1,125	1,115	1,098	1,041	1,023	1,011	1,002	995	992	880	877	796	790	784
Shares Outstanding	0.3%	206	206	190	189	189	188	186	185	185	179	178	178	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,323	-	1,949	-	-	-	-	-	2,801	-	-	-	833	-	-	-	414	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-502.0%	-53,684	-8,918	-19,897	-18,814	-47,512	-23,849	-32,444	-27,757	-77,800	-32,459	-23,276	-25,411	-61,011	-42,531	-38,255	-31,041	-23,281	-10,448	-27,637	-24,501	-26,998
Share Based Compensation	-17.2%	13,652	16,488	12,279	12,841	14,007	15,282	9,951	9,867	9,601	8,500	13,029	7,632	5,479	5,887	2,873	3,280	2,754	3,688	5,329	5,385	3,317
Cashflow From Investing	201.0%	28,756	-28,473	23,119	-19,035	-107,109	77,215	-69,543	-97,438	-38,472	-11,120	7,747	4,504	14,673	21,414	-34,062	-4,932	10,724	16,261	23,514	22,278	15,881
Cashflow From Financing	67.0%	-1,048	-3,173	1,225	29,356	5,077	4,199	76,325	147	7,356	347,418	4,776	4,574	2,900	196,760	-4,634	108,197	266	78,460	184	414	20,040

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BCRX Income Statement

2024-03-31

Condensed Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Revenues	$ 92,761	$ 68,778
Expenses:
Cost of product sales	1,265	931
Research and development	46,493	48,388
Selling, general and administrative	59,364	47,867
Royalty	127	7
Total operating expenses	107,249	97,193
Loss from operations	(14,488)	(28,415)
Interest income	4,031	3,378
Interest expense	(24,506)	(27,396)
Foreign currency losses, net	(51)	(229)
Loss before income taxes	(35,014)	(52,662)
Income tax expense	365	671
Net loss	(35,379)	(53,333)
Foreign currency translation adjustment	(253)	59
Unrealized (loss) gain on available for sale investments	(313)	500
Net comprehensive loss	$ (35,945)	$ (52,774)
Basic net loss per common share (in usd per share)	$ (0.17)	$ (0.28)
Diluted net loss per common share (in usd per share)	$ (0.17)	$ (0.28)
Weighted average shares outstanding, basic (in shares)	206,064	188,509
Weighted average shares outstanding, diluted (in shares)	206,064	188,509

BCRX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets
Cash and cash equivalents	$ 84,333	$ 110,643
Restricted cash	1,798	1,804
Investments	252,221	278,344
Trade receivables	60,586	56,950
Inventory, net	29,781	28,683
Prepaid expenses and other current assets	18,381	19,542
Total current assets	447,100	495,966
Property and equipment, net	7,831	7,910
Other assets	12,961	13,084
Total assets	467,892	516,960
Liabilities and Stockholders’ Deficit
Accounts payable	11,910	20,893
Accrued expenses	79,249	102,882
Operating lease liabilities	1,098	1,058
Finance lease liabilities	1,642	1,590
Royalty financing obligations	26,022	23,565
Total current liabilities	119,921	149,988
Operating lease liabilities	8,596	8,390
Finance lease liabilities	2,506	2,845
Royalty financing obligations	504,552	508,034
Secured term loan	308,484	303,231
Stockholders’ deficit:
Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding – 206,347 at March 31, 2024 and 205,771 at December 31, 2023	2,063	2,058
Additional paid-in capital	1,237,537	1,222,236
Accumulated other comprehensive income	771	1,337
Accumulated deficit	(1,716,538)	(1,681,159)
Total stockholders’ deficit	(476,167)	(455,528)
Total liabilities and stockholders’ deficit	$ 467,892	$ 516,960

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

CEO	Mr. Jon P. Stonehouse
WEBSITE	biocryst.com
INDUSTRY	Biotechnology
EMPLOYEES	531

BioCryst Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for BioCryst Pharmaceuticals Inc? What does BCRX stand for in stocks?

BCRX is the stock ticker symbol of BioCryst Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioCryst Pharmaceuticals Inc (BCRX)?

As of Wed May 08 2024, market cap of BioCryst Pharmaceuticals Inc is 1.05 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCRX stock?

You can check BCRX's fair value in chart for subscribers.

What is the fair value of BCRX stock?

You can check BCRX's fair value in chart for subscribers. The fair value of BioCryst Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioCryst Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioCryst Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether BCRX is over valued or under valued. Whether BioCryst Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact BioCryst Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCRX.

What is BioCryst Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, BCRX's PE ratio (Price to Earnings) is -5.05 and Price to Sales (PS) ratio is 2.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioCryst Pharmaceuticals Inc's stock?

In the past 10 years, BioCryst Pharmaceuticals Inc has provided -0.04 (multiply by 100 for percentage) rate of return.